



FOR IMMEDIATE RELEASE

SUSTAINED NANO SYSTEMS, LLC TO REPORT ON THE EXTENDED RELEASE OF MEDICAL CANNABIS AT THE BIOTECH SHOWCASE IN SAN FRANCISCO, JANUARY 9, 2019.

New York, NY – December 31, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”) a privately-held biopharmaceutical company has announced positive results in its ability to incorporate medical cannabis into its bio-resorbable nano and microparticles for long term medical delivery.

The field of medical cannabis is one of the fastest growing categories in the pharmaceutical area. SNS has carried out research on the use of medical cannabis for extended release. Evidence suggests that cannabis may be effective in treating seizure activity (epilepsy), neurologic disorders, chronic pain, post-traumatic stress disorder, and inflammatory disease.

At the present time the methods of delivery of cannabinoids are limited to smoking, vaporizing, oil, capsule, and cookies. Recently, an oral mucosal spray has proved viable in anti-seizure treatment, but the short duration of effect and time to pharmacologic onset has proven difficult. As a result, the potential for a long acting sustained drug in chronic conditions may be beneficial.

To alleviate this problem, SNS utilized its patented delivery system to incorporate cannabinoid into its microparticles. In-vitro results demonstrated that CBD was released over extended periods from days to months, suggesting the potential to deliver sustained levels as prescribed.

In addition to medical cannabis, Dr. Barry Libin, CEO, will report on the effectiveness of the SNS Platform to deliver extended duration of small and macromolecules, including monoclonal antibodies, to treat diseases of the eye.

The presentation will be held on Wednesday, January 9, at 3:30 at the Hilton San Francisco Union Square. Track: Franciscan B (Ballroom Level)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for the prevention and treatment of chronic disease. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term continuous micro-dosing of drugs to targeted tissue as prescribed. The basis of the SNS pipeline is its patented technology incorporating bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology. SNS seeks to license its technology where sustained delivery is required, and collaborate with financial partners to support its development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Dr. Barry Libin
[\(516\) 353-7983](tel:5163537983)
barlibin@gmail.com

Media Relations
Info@newsfrontmedia.com

You are subscribed to Sustained Nano Systems, LLC Investor Relations e-mail alerts:
To unsubscribe please send to info@newsfrontmedia.com